"BUSINESS WIRE https Ltd. TSE Hitachi today announced that Johns Hopkins Medicine has selected Hitachi to provide its proton beam therapy httpcts.businesswire.comctCTidsmartlinkurlhttpAFF PBT system at Sibley Memorial Hospital located in Washington D.C. This collaboration which includes a year maintenance service marks the first multiroom PBT application in the nations capital. This will be Hitachis fifth PBT system in North America.  The nextgeneration system PROBEAT which comes with IMPT Intensity Modulated Proton Therapy and conebeam CT will have improved spot scanning capability in all  gantrytype treatment rooms along with a fixed irradiation room dedicated to cancer research.  Toshiaki Higashihara President  COO of Hitachi Ltd. stated that We are greatly honored that Johns Hopkins selected Hitachi as their proton partner. As one of the leaders in cancer research and treatment the Johns Hopkins Sidney Kimmel Comprehensive Cancer Centers philosophy of being at the leading edge of cancer treatment through research and development is very similar to our Social Innovation concept which supports a healthy and secure society through innovative technologies systems solutions and services. The proton center at Sibley Memorial Hospital will be an impressive demonstration of industry and academic medicine collaborating to bring a new technology and new cancer treatment modality to Washington D.C. and the surrounding communities. Thus we foresee an exciting long term relationship that will benefit cancer patients and cancer research.  In December  Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special k for the PROBEAT system with its spot scanning irradiation technology. Hitachi has delivered the first hospital based spot scanning system in May  and has treated over  patients to date. The same spot scanning system has already been installed at Nagoya Proton Therapy Center and Hokkaido University in Japan. In fiscal year  ending March  one of Hitachis new PBT site is planning to start treatment of patients. Hitachi has shown great stability in the proton market through continued investment in research and development track record for high clinical availability of over  along with a commitment to a long term partnership with all of its clients.  Given the growing demand for technical and clinical advancements in the treatment of cancer interest in proton therapy is on the rise with more and more hospitals and cancer treatment facilities venturing into this area. Hitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution and contribute to cancer treatment around the world.  Overview of Proton Beam Therapy  Proton Beam Therapy PBT is an advanced type of cancer radiotherapy. Protons from a hydrogen atom are extracted and accelerated up to  the speed of light. Its energy is concentrated directly on the tumor while avoiding radiation dose to the surrounding healthy tissues. PBT improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy. In most cases patients can continue with their normal daily activities while undergoing treatment. Because there are fewer side effects PBT is expected to expand especially for pediatric treatment.  Overview of Spot Scanning Technology  Unlike conventional scattering technology spot scanning technology delivers narrow beams to the tumor and the complex tumor shape can be irradiated through repetitive beam delivery with quick position change. Spot scanning technology has been achieved by advancing the uniform quality beam extraction technology from the accelerator and beam control technology with high accuracy. Three primary benefits are  more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation  patientspecific collimators and boluses become obsolete shortening set up times for patients and  high proton beam usage factor reducing unnecessary secondary radiation.  About Hitachi Ltd.  Hitachi Ltd. TSE  headquartered in Tokyo Japan delivers innovations that answer societys challenges with our talented team and proven experience in global markets. The companys consolidated revenues for fiscal  ended March   totaled  billion yen . billion. Hitachi is focusing more than ever on the Social Innovation Business which includes power  infrastructure systems information  telecommunication systems construction machinery high functional materials  components automotive systems healthcare and others. For more information on Hitachi please visit the companys website at http httpcts.businesswire.comctCTidsmartlinkurlhttpAFF"